Total amount: € 0,00
HOW TO ORDER
A Journal on Internal Medicine
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6
Panminerva Medica 1999 March;41(1):68-71
Serum and salivary antiendomysium antibodies in the screening of coeliac disease
Di Leo M., Weisz G.*, Ansaldi Balocco N.
From the Department of Pediatrics and Adolescence Sciences Chair of Pediatrics, Gastroenterology Section University of Turin and the *Analysis Laboratory, Martini Nuovo Hospital, Turin, Italy
Background. Antiendomysium antibodies (EMA) detection in serum is the best screening test for coeliac disease (CD): in saliva it has not yet been assayed. Aims of this study are: to verify the presence of EMA in saliva collected with a not invasive technique; to evaluate the validity of serum and salivary EMA in CD screening.
Methods. We investigated 130 subjects divided into 3 groups: “A”: 45 untreated CD patients (mean age 6.11); “B”:18 CD patients treated with a gluten free diet (mean age 13.2); “C”: 67 controls ( mean age 8.9). We performed the EMA test using the indirect immunofluorescence technique, in serum and in saliva concentrated samples.
Results. Our results show: sensitivity EMA serum 100%; specificity EMA serum 96.5%; sensitivity EMA saliva 46.5%; specificity EMA saliva 100%; pos. pred. value EMA serum 93.5%; neg. pred. value serum 100%; pos. pred. value EMA saliva 100%; neg. pred. value saliva 78.7%.
Conclusions. Conclusion indicates a high specificity of salivary EMA and a high sensitivity of serum EMA, anyway biopsy is still recommended for diagnosis of CD.